IPO Year: 2024
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/22/2025 | $21.00 | Buy | Craig Hallum |
| 3/17/2025 | $20.00 | Buy | H.C. Wainwright |
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
- Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients - Prolonged and Durable Complete Responses (CRs) Observed in Two of Ten Refractory Ewing Sarcoma Patients - Two Additional Patients Had Durable Stable Disease in Notoriously Difficult-to-Treat Cancer - Confirmed Partial Response (PR) in a patient with a desmoplastic small-round-cell tumor (DSRCT) - Company Initiating Planning of Phase 2 Trial of Elraglusib in Children, Adolescents, and Adults with Refractory/Resistant Ewing Sarcoma CHICAGO and FORT WORTH, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical
- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) vs GnP alone - Patients with liver metastases experienced a 2.5x improvement in 1-year OS with a 38% reduction in risk of death when treated with elraglusib plus GnP CHICAGO and FORT WORTH, Texas, June 24, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the in
CHICAGO and FORT WORTH, Texas, June 20, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced biomarker data from a recent poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic adenocarcinoma (mPDAC). The study demonstrated the use of machine learning an
Inclusion reflects continued growth and momentum in the company's mission to transform the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced today that the Company will be added to the Russell 3000® Index, with automatic inclusion in the Russell 2000® Index, effective after the U.S. market close on June 27, as part of the 2025 Rus
- Expert Insights on Clinical Relevance and Scientific Rationale- The replay of the event is available on the Investor Relations section of the Actuate website CHICAGO and FORT WORTH, Texas, June 02, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced key takeaways from its Key Opinion Leader (KOL) event held on May 31, 2025 discussing the positive topline results from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in com
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving elraglusib/GnPRisk of death was reduced by 37% (HR=0.63) in patients treated with elraglusib/GnPData featured as an oral presentation at the ASCO Annual MeetingCompany plans to engage with FDA in the second half of 2025 to align on a path towards product registrationCompany to host KOL event today at 6:30 pm CDT to discuss 1801 Part 3B results CHICAGO and FORT WORTH, Texas, May 31, 2025 (GLOBE NEWSWIRE) -- Actua
Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)Oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting to highlight statistically significant improvement in median overall survival and 1-year survival rate in patients treated with the combination of elraglusib and gemcitabine/nab-paclitaxel (GnP) compared to GnP aloneCompany to host KOL event on May 31, 2025, to review data presented CHICAGO and FORT WORTH, Texas, May 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clin
Fireside discussion to explore clinical impact of the topline Phase 2 data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) to be presented at ASCOIn-person event and virtual webcast to be held on Saturday, May 31, 2025, at 6:30 pm CDT CHICAGO and FORT WORTH, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it will host an in-person key opinion leader (KOL) event, during the 2025 American
Topline data shows statistically significant improvement in overall survival in elraglusib plus GnP combination arm versus GnP control armElraglusib/GnP combination arm demonstrated substantial improvement in median overall survival since the last data analysisClinical trial meets primary endpoint for overall survival and confirms significant 1-year survival rateElraglusib/GnP combination arm demonstrated a favorable risk-benefit profileTopline dataset to be presented in an oral presentation at the upcoming ASCO Annual Meeting Company plans to work with regulators to expeditiously bring elraglusib to commercialization CHICAGO and FORT WORTH, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Actua
CHICAGO and FORT WORTH, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President & Chief Executive Officer of Actuate will present at the Citizens Life Sciences Conference 2025 taking place May 7-8 in New York, NY. Citizens JMP Life Sciences Conference Presentation Date:Thursday, May 8, 2025Time:12:30 PM ETWebcast Link:click here The webcast of the presentation will be accessib
HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati
SC 13D - ACTUATE THERAPEUTICS, INC. (0001652935) (Subject)
D - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
S-8 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
10-Q - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
EFFECT - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
424B3 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
Craig Hallum initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $21.00
H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00